The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Transaction in Own Shares

9 Aug 2017 07:00

RNS Number : 4521N
Immunodiagnostic Systems Hldgs PLC
09 August 2017
 

Immunodiagnostic Systems Holdings plc

Transaction in Own Shares

9 August 2017

Immunodiagnostic Systems Holdings plc (IDH.L) ("IDS" or the "Company"), a specialist producer of manual and automated diagnostic testing kits and instrumentation for the clinical and research markets, announces that it has purchased (through Peel Hunt LLP acting as the Company's broker) the following number of its shares of 2p each on the London Stock Exchange. The purchased shares will be held as treasury shares.

The purchases were made pursuant to the buy-back programme announced on 21 June 2017.

Date of purchase:

8th August 2017

Number of shares purchased (aggregated volume):

273

Highest price paid per share (pence):

298.9157p

Lowest price paid per share (pence):

298.9157p

Volume weighted average price paid per share (pence):

298.9157p

 

Following the purchase of these shares, IDS holds 1,905 ordinary shares as treasury shares and the Company's issued share capital (excluding shares held as treasury shares) consists of 29,413,270 shares. All of the shares have equal voting rights. This figure 29,413,270 represents the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), detailed information about the individual purchases made by Peel Hunt on the Company's behalf is set out in the schedule below.

For further information:

Immunodiagnostic Systems Holdings plc

Tel : +44 (0)191 519 0660

Paul Martin, Group Finance Director

Peel Hunt LLP

Tel : +44 (0)207 418 8900

James Steel

Oliver Jackson

 

Schedule of Purchases - Individual Transactions

Number of shares purchased

Transaction price(pence per share)

Time of transaction

Trading venue

273

298.9157

14:21:24

London Stock Exchange

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
POSQVLFBDVFFBBQ

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.